Figure 6
DCs were recruited into tumor tissues one day after HIFU treatment and exhibited the surface phenotype of maturation. (A) The presence of CD45+ tumor-infiltrating leukocytes in tumor tissues was identified in the gate indicated. (B) CD11c+ cells in the gate defined in A were analyzed for the expression of MHC II, CD80, and CD86. Representative data of six independent experiments with consistent results are shown. (C) The proportion of tumor-infiltrating DC (CD11c+/MHC II+) (expressed in percentage of total cells) was investigated for the indicated tumors one day after different HIFU-treatment. (D) The expression levels of CD86 (presented as mean fluorescence intensity) were analyzed in CD11c+ cells infiltrating B16 or MC-38 tumor one day after different HIFU-treatment. (E) The expression levels of CD80 (presented as mean fluorescence intensity) were analyzed in CD11c+ cells infiltrating B16 or MC-38 tumor one day after different HIFU-treatment. (C-E) Results were expressed as mean ± SD for each group (n = 6 per group). *P < 0.05 versus non-treatment control; #P < 0.05 versus Dense-scan HIFU by Student's t test. This experiment is representative of three experiments with consistent results.